{
  "id": 16741095,
  "title": "Can a Digital Pill Help Treat Depression? Meron Gribetz on Brain Tech",
  "url": "https://urgent.news/2026/10/27/can-a-digital-pill-help-treat-depression-meron-gribetz-on-brain-tech",
  "topic": "ai",
  "section": "AI",
  "published": "2026-10-27T11:44:57.000Z",
  "source": {
    "name": "Colombia One",
    "slug": "colombia-one",
    "url": "https://colombiaone.com/2026/10/27/digital-pill-help-treat-depression-meron-gribetz/"
  },
  "original_language": "en",
  "account": "Meron Gribetz has dedicated his career to making technology more natural and essential to human life. His work has spanned from augmented reality to neurotechnology, always asking if technology can adapt to people instead of the other way around. Now as founder and CEO of Inner Cosmos, he is exploring how this principle applies to mental health, specifically treatment-resistant depression. Gribetz's journey with mental health began at a young age. Diagnosed with ADHD at 10, he was prescribed Ritalin, which helped academically but raised questions about its impact on his social life and overall well-being. This personal experience became the catalyst for his current work. The company's flagship product, the \"Digital Pill,\" is a brain implant designed to stimulate the circuits linked to depression. It works alongside external technology to support treatment at home and monitor progress. However, the device is still in clinical evaluation, and its long-term benefits, safety, and integration into depression care need to be established through further research. Gribetz's challenge lies in bringing this ambitious technological concept into a field where people's health, trust, and daily lives are at stake. Before focusing on mental health, Gribetz worked on augmented reality and exploring new ways for humans to interact with computers. His 2016 TED talk touched on the question of whether technology is enhancing or diminishing human connection. He envisioned a \"natural machine\" that would work in harmony with how people naturally think, move, and perceive. This vision of technology led him to neurotechnology and the Digital Pill. While the Digital Pill offers a new approach to treating depression, it raises important questions. What do clinical studies reveal about its effectiveness? Which patients could benefit most from this approach? How can patient safety, privacy, and control be maintained during the development process? In mental health, where people often seek hope after experiencing treatment failures, these questions are particularly crucial. For Gribetz, the ultimate goal of technology is to improve people's lives. Whether it's reconnecting with family, returning to a beloved activity, or envisioning a future that once seemed unattainable, technology can expand the options available to those living with depression. As Inner Cosmos' Digital Pill continues to be studied, its core ambition remains evident: to investigate if innovation can broaden the possibilities for individuals battling depression.",
  "summary": "Meron Gribetz has spent much of his career asking how technology can become a more natural part of human life. His work has taken him from augmented reality to neurotechnology, but the question at its heart remains remarkably consistent: Can technology adapt to people, rather than asking people to adapt to it? As founder and CEO […]",
  "key_points": [
    "Meron Gribetz dedicates career to natural human-tech integration",
    "Inner Cosmos develops Digital Pill for treatment-resistant depression",
    "Device's long-term benefits, safety, and integration need further research"
  ],
  "editors_take": "Moving neurotechnology into the mental health space shifts the treatment paradigm for depression from traditional medication toward implanted devices that aim to harmonize with human neural circuits.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}